¼¼°èÀÇ µ¿¹°¿ë ¾È°ú ÀÇ·á ½ÃÀåÀº 2024-2032³â CAGR 3.5%¸¦ ±â·ÏÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
ÀÌ´Â ¼öÀÇ ¾È°úÇÐÀÇ ¹ßÀü°ú ¾È°ú Àü¹® Á¦Ç°ÀÇ µµÀÔ¿¡ µû¶ó ¹Ý·Áµ¿¹°ÀÇ ¾È°ú Áúȯ ¹ß»ý·üÀÌ ³ô¾ÆÁø µ¥ µû¸¥ °ÍÀÔ´Ï´Ù. ¹Ý·Áµ¿¹°Àº ¹é³»Àå, ³ì³»Àå, °¨¿°¼º Áúȯ°ú °°Àº ÈçÇÑ Áúº´¿¡ Á÷¸éÇϰí ÀÖÀ¸¸ç, È¿°úÀûÀÎ Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä°¡ Å®´Ï´Ù. ¶ÇÇÑ ÃֽŠÁø´Ü Åø¿Í Çõ½ÅÀûÀÎ Ä¡·á¹ýÀÇ °³¹ß·Î Ä¡·áÀÇ ÁúÀÌ Çâ»óµÇ°í ÀÖ½À´Ï´Ù. ÀÌ´Â µ¿¹°¿ë ¾È°ú ÀÇ·á »ê¾÷ÀÌ ¼ºÀåÇÒ ¼ö ÀÖ´Â À¯¸ÁÇÑ È¯°æÀ» Á¶¼ºÇϰí ÀÖÀ¸¸ç, ¹Ý·Áµ¿¹°ÀÇ ´« °Ç°À» À§ÇØ ¹Ý·Áµ¿¹° º¸È£ÀÚµéÀÇ ¿ä±¸°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.
¿¹¸¦ µé¾î 2024³â 1¿ù, ENTOD Pharmaceuticals´Â ¹Ý·Áµ¿¹°¿ë ¾È°ú ¹× À̺ñÀÎÈİú Ä¡·áÁ¦¸¦ Á¦°øÇÏ´Â ºÎ¼ÀÎ FURÀ» ¼³¸³ÇÏ¿© À±È° Á¡¾ÈÁ¦, Ç׳쳻ÀåÁ¦, Ç׾˷¹¸£±âÁ¦, Ç×»ýÁ¦, º¹ÇÕÁ¦ µî ´Ù¾çÇÑ µ¿¹°¿ë ¼Ö·ç¼ÇÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ´Â ¹Ý·Áµ¿¹° °Ç° Á¦Ç°¿¡ ´ëÇÑ Àνİú ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó ¹Ý·Áµ¿¹°ÀÇ Æ¯Á¤ ´«°ú ±Í Áõ»ó¿¡ ´ëÇÑ ´ëÀÀ¿¡ Á¡Á¡ ´õ ÃÊÁ¡À» ¸ÂÃß°í ÀÖÀ½À» ½Ã»çÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå °³Ã´Àº Çõ½ÅÀûÀÎ Ä¡·á¹ýÀ» Á¦°øÇÏ°í µ¿¹°¿ë ¾È°ú ¹× À̺ñÀÎÈİú Ä¡·á ¿É¼ÇÀ» º¸´Ù ±¤¹üÀ§ÇÏ°Ô Á¦°øÇÔÀ¸·Î½á ½ÃÀå ¼ºÀå¿¡ ±â¿©ÇÒ ¼ö ÀÖ½À´Ï´Ù.
µ¿¹°¿ë ¾È°ú ÀÇ·á ½ÃÀåÀº Á¦Ç° ¹× ¼ºñ½º, µ¿¹° À¯Çü, ÀûÀÀÁõ, ÃÖÁ¾ ¿ëµµ, Áö¿ªº°·Î ¼¼ºÐȵǾî ÀÖ½À´Ï´Ù.
°í¾çÀÌ ºÎ¹®Àº °í¾çÀÌÀÇ °Ç°, ƯÈ÷ ¼¶¼¼ÇÑ ´«ÀÇ °Ç°¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼ 2024-2032³â ´«¿¡ ¶ç°Ô ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Àü ¼¼°è °í¾çÀÌ ÁÖÀεéÀº ¿¹¹æ Á¶Ä¡ºÎÅÍ °í±Þ Ä¡·á±îÁö Á¾ÇÕÀûÀÎ ¾È°ú Ä¡·á¸¦ ¿ì¼±¼øÀ§·Î »ï°í ÀÖ½À´Ï´Ù. °í¾çÀÌ´Â Àü ¼¼°è¿¡¼ Àαâ ÀÖ´Â ¹Ý·Áµ¿¹°À̱⠶§¹®¿¡ ÀÌ ºÎ¹®¿¡ ´ëÇÑ °ü½ÉÀº ²ÙÁØÈ÷ Áõ°¡ÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ¹Ý·Á¹¦¿Í ¹Ý·Á¹¦ÀÇ À¯´ë°¨ÀÌ ±í¾îÁü¿¡ µû¶ó ´« °Ç°À» ÃÖÀûÀ¸·Î À¯ÁöÇÏ´Â °ÍÀÌ Áß¿äÇÏ´Ù´Â ÀνÄÀÌ ³ô¾ÆÁö¸é¼ °í¾çÀÌ ºÎ¹®Àº µ¿¹°¿ë ¾È°ú ÀÇ·á »ê¾÷ÀÇ Áß¿äÇÑ ÃËÁøÁ¦°¡ µÇ°í ÀÖ½À´Ï´Ù.
Áø´Ü ½ÇÇè½Ç ºÎ¹®Àº ¹Ý·Áµ¿¹°ÀÇ ´Ù¾çÇÑ ¾È°ú ÁúȯÀ» Àû½Ã¿¡ Á¤È®ÇÏ°Ô Áø´ÜÇϰíÀÚ ÇÏ´Â ¼ö¿ä Áõ°¡¿¡ ÈûÀÔ¾î 2032³â±îÁö °ß°íÇÑ ¼ºÀå¼¼¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ·¯ÇÑ Àü¹® °Ë»ç½ÇÀº ÷´Ü Áø´Ü Åø¿Í Àü¹® Áö½ÄÀ» Á¦°øÇÏ¿© ¼öÀǻ簡 ¾È°ú ÁúȯÀ» Á¤È®ÇÏ°Ô ½Äº°ÇÒ ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù. ¹Ý·Áµ¿¹°ÀÇ °Ç°¿¡ ´ëÇÑ º¸È£ÀÚµéÀÇ °ü½ÉÀÌ ³ô¾ÆÁü¿¡ µû¶ó Á¤¹ÐÇÑ ¾È°ú °Ë»ç¸¦ Á¦°øÇÏ´Â Áø´Ü °Ë»ç ±â°ü¿¡ ´ëÇÑ ½Å·Ú°¡ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ¾È°ú ÁúȯÀ» ½Äº°ÇÏ°í °ü¸®ÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» ÇÏ´Â Áø´Ü°Ë»ç½Ç ºÎ¹®Àº ¹Ý·Áµ¿¹° ÇコÄÉ¾î »ê¾÷ÀÇ ¼ºÀå¿¡ ÀÖÀ¸¸ç, ¸Å¿ì Áß¿äÇÑ ¿ä¼Ò·Î ÀÚ¸® Àâ°í ÀÖ½À´Ï´Ù.
¾Æ½Ã¾ÆÅÂÆò¾çÀÇ µ¿¹°¿ë ¾È°ú ÀÇ·á ½ÃÀå ±Ô¸ð´Â 2024-2032³â »ó´çÇÑ CAGRÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±Þ¼ÓÇÑ µµ½ÃÈ, ¹Ý·Áµ¿¹° »çÀ°·ü Áõ°¡, µ¿¹° °Ç°¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼ ÀÌ·¯ÇÑ Ãß¼¼¸¦ ÁÖµµÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ¶ÇÇÑ ÀÌ Áö¿ªÀÇ °¡Ã³ºÐ ¼ÒµæÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ¹Ý·Áµ¿¹° ÇコÄɾ ´ëÇÑ ÁöÃâÀ» ´Ã¸± ¼ö ÀÖ½À´Ï´Ù. ¼öÀÇ ¾È°ú ºÐ¾ßÀÇ ±â¼ú ¹ßÀüµµ Áø´Ü ¹× Ä¡·á ¿É¼ÇÀ» ´Ã¸®´Â µ¥ ÇѸòÇϰí ÀÖ½À´Ï´Ù. ¾çÁúÀÇ ¾È°ú Ä¡·á¸¦ ¿øÇÏ´Â º¸È£ÀÚ°¡ Áõ°¡ÇÔ¿¡ µû¶ó ¾Æ½Ã¾ÆÅÂÆò¾çÀº ¼¼°è ¼öÀÇ ¾È°ú ÀÇ·á »ê¾÷ÀÇ ¼ºÀå¿¡ Å©°Ô ±â¿©ÇÏ´Â Áö¿ªÀÌ µÉ °ÍÀÔ´Ï´Ù.
Global Veterinary Eye Care Market will register 3.5% CAGR between 2024 and 2032, driven by the high incidence of eye conditions in pets, in line with advancements in veterinary ophthalmology and the introduction of specialized eye care products. With pets facing common ailments like cataracts, glaucoma, and infections, the demand for effective treatments is significant. Furthermore, the development of modern diagnostic tools and innovative treatments enhances the quality of care. This creates a promising landscape for the expansion of the veterinary eye care industry, catering to the increasing needs of pet owners seeking optimal eye health for their companions.
For instance, in January 2024, ENTOD Pharmaceuticals introduced 'FUR,' a division offering eye and ear care medicines for pets. FUR provides a diverse range of veterinary solutions, including lubricating drops, anti-glaucoma medications, anti-allergies, antibiotics, and combinations. It reflects the growing awareness and demand for pet health products, suggesting an increasing focus on addressing specific ocular and aural conditions in pets. This development could contribute to the market growth by offering innovative treatments and enhancing the availability of veterinary eye and ear care options on a broader scale.
The veterinary eye care market is fragmented based on products and services, animal type, indication, end-use, and region.
The feline segment will witness a notable expansion over 2024-2032, fueled by a growing emphasis on feline health, particularly their delicate ocular needs. Cat owners worldwide are increasingly prioritizing comprehensive eye care, from preventive measures to advanced treatments. With cats being popular pets globally, this segment's prominence could grow steadily. As the bond between owners and their feline companions strengthens, so does the recognition of the importance of maintaining optimal eye health, making the feline segment a key driver in the veterinary eye care industry.
The diagnostic laboratories segment will exhibit a healthy growth rate through 2032, propelled by the increasing demand for accurate and timely diagnoses of various eye conditions in pets. These specialized laboratories offer advanced diagnostic tools and expertise, aiding veterinarians in pinpointing ocular diseases with precision. As pet owners become more proactive about their pets' health, the reliance on diagnostic laboratories for thorough eye examinations grows. With their crucial role in identifying and managing eye issues, the diagnostic laboratories segment will emerge as a pivotal component of the pet care industry's growth.
Asia Pacific veterinary eye care market size will experience a substantial CAGR from 2024 to 2032. Rapid urbanization, increasing pet adoption rates, and a growing awareness of animal health drive this trend. Moreover, the region's rising disposable incomes allow for greater spending on pet healthcare. Technological advancements in veterinary ophthalmology also play a role in enhancing diagnosis and treatment options. With an increasing number of pet owners seeking high-quality eye treatments, the Asia Pacific region will stand as a remarkable contributor to the global veterinary eye care industry growth.